Untitled record

The present application relates to antibodies and their fragments that are immunoreactive to the B7-H3 receptor in mammals, and more particularly, to the B7-H3 receptor in humans and to the uses thereof, particularly in the treatment of cancer and the inflammation. Iio, therefore, particularly refers to humanized B7-H3 reactive antibodies and their immunoreactive fragments that are capable of mediating, and more preferably enhancing, the activation of the immune system against cancer cells that are associated with a variety of cancers. humans. Claim 2: The isolated antibody or immunoreactive fragment thereof according to claim 1, said antibody or said CHARACTERIZED fragment because it comprises a variable domain comprising: (A) CDR1 (SEQ ID NO: 21), CDR2 (SEQ ID NO: 23) and CDR3 (SEQ ID NO: 25) of the light chain of BRCA69D and CDR, (SEQ ID NO: 29), CDR2 (SEQ ID NO: 31) and CDR3 (SEQ ID NO: 33) of the heavy chain of BRCA69D; (B) CDR1 (SEQ ID NO: 5), CDR2 (SEQ ID NO: 7) and CDR3 (SEQ ID NO: 9) of the BRCA84D light chain and CDR1 (SEQ ID NO: 13), CDR2 (SEQ ID NO: : 15) and CDR3 (SEQ ID NO: 17) of the BRCA84D heavy chain; or (C) CDR1 (SEQ ID NO: 37), CDR2 (SEQ ID NO: 39) and CDR3 (SEQ ID NO: 41) of the light chain of PRCAI57 and CDR1 (SEQ ID NO: 45), CDR2 (SEQ ID NO: 47) and CDR3 (SEQ ID NO: 49) of the heavy chain of PRCAI57.